Abstracts tagged "Osteoblasts"

Abstract Number: 1001 • 2014 ACR/ARHP Annual Meeting
Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1
Satoshi Yamasaki and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: There is evidence of osteoclast activation in the inflamed joints of patients with rheumatoid arthritis (RA). Studies that focus on osteoblasts are not sufficient…
Abstract Number: 609 • 2014 ACR/ARHP Annual Meeting
Induced Pluripotent Stem Cells (iPSCs) As a Tool for Unraveling the Role of Different Cell Types in the Disease Process of Spondyloarthritis Pathogenesis
Gerlinde Layh-Schmitt¹, Shjia Lu², Fatemeh Navid², Massimo Gadina² and Robert A. Colbert², ¹10 Center Drive., NIAMS/NIH, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: Many genetic factors and cell types contribute to the axial inflammation, trabecular bone loss, and aberrant bone formation that result in ankylosing spondylitis. The…
Abstract Number: 2072 • 2012 ACR/ARHP Annual Meeting
Bone Formation and Resorption Are Both Increased in Autoimmune Arthritis
Kresten K. Keller¹, Jesper Skovhus Thomsen², Kristian Stengaard-Pedersen¹, Frederik Dagnæs-Hansen³, Jens R. Nyengaard⁴ and Ellen-Margrethe Hauge¹, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Institute of Anatomy, Aarhus University, ³Institute of Medical Microbiology and Immunology, Aarhus University, Aarhus, Denmark, ⁴Stereology and Electron Microscopy Laboratory, Centre for Stochastic Geometry and Advanced Bioimaging. Aarhus University hospital, Aarhus, Denmark
Background/Purpose: Bone destruction in the joints of patients with rheumatoid arthritis (RA) is the result of a combination of osteoclastic bone resorption and osteoblastic bone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].